Country: United States
Language: English
Source: NLM (National Library of Medicine)
ESTAZOLAM (UNII: 36S3EQV54C) (ESTAZOLAM - UNII:36S3EQV54C)
Rebel Distributors Corp
ESTAZOLAM
ESTAZOLAM 2 mg
ORAL
PRESCRIPTION DRUG
Estazolam tablets are indicated for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Both out-patient studies and a sleep laboratory study have shown that estazolam administered at bedtime improved sleep induction and sleep maintenance (see CLINICAL PHARMACOLOGY ). Because insomnia is often transient and intermittent, the prolonged administration of estazolam is generally neither necessary nor recommended. Since insomnia may be a symptom of several other disorders, the possibility that the complaint may be related to a condition for which there is a more specific treatment should be considered. There is evidence to support the ability of estazolam to enhance the duration and quality of sleep for intervals up to 12 weeks (see CLINICAL PHARMACOLOGY ). Benzodiazepines may cause fetal damage when administered during pregnancy. An increased risk of congenital malformations associated with the use of diazepam and chl
Estazolam Tablets, 2 mg are dark pink, scored, diamond shaped compressed tablets imprinted with WATSON on one side of the tablet and on the other side with 745 on the left side of the score and 2 on the right side of the score, supplied in bottles of 30. Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.] Dispense in a tight, light-resistant container as defined in the USP. Manufactured By: Watson Laboratories, Inc. Corona, CA 92880 USA Distributed By: Watson Pharma, Inc. Corona, CA 92880 USA Repackaged by: Rebel Distributors Corp Thousand Oaks, CA 91320
Abbreviated New Drug Application
ESTAZOLAM- ESTAZOLAM TABLET REBEL DISTRIBUTORS CORP ---------- ESTAZOLAM TABLETS CIV REVISED: SEPTEMBER 2008 RX ONLY 14444-2 DESCRIPTION Estazolam, a triazolobenzodiazepine derivative, is an oral hypnotic agent. Estazolam occurs as a fine, white, odorless powder that is soluble in alcohol and practically insoluble in water. The chemical name for estazolam is 8-chloro-6-phenyl-4_H_-_s_-triazolo[4,3-α][1,4]benzodiazepine. The molecular formula is C H CIN and its molecular weight is 294.75. The structural formula is represented as follows: Each tablet, for oral administration, contains 1 mg or 2 mg estazolam. In addition, each tablet contains the following inactive ingredients: docusate sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium benzoate, sodium starch glycolate and stearic acid. The 2 mg tablets also contain FD&C Red #40 aluminum lake. CLINICAL PHARMACOLOGY PHARMACOKINETICS _Absorption_ Estazolam tablets have been found to be equivalent in absorption to an orally administered solution of estazolam. In healthy subjects who received up to three times the recommended dose of estazolam, peak estazolam plasma concentrations occurred within two hours after dosing (range 0.5 to 6 hours) and were proportional to the administered dose, suggesting linear pharmacokinetics over the dosage range tested. _Distribution_ Independent of concentration, estazolam in plasma is 93% protein bound. _Metabolism_ Estazolam is extensively metabolized. Only two metabolites (1-oxo-estazolam and 4-hydroxy- estazolam) were detected in human plasma up to 18 hours. The pharmacologic activity of estazolam is primarily from the parent drug. The elimination of the parent 16 11 4 drug takes place via hepatic metabolism of estazolam to hydroxylated and other metabolites that are eliminated largely in the urine both free and conjugated. In humans, greater than 70% of a single dose of estazolam was recovered in the urine as metabolites. Less than 5% of a 2 mg dose of estazolam was excreted unchanged in the urine Read the complete document